Ori Ben-Yehuda
NewYork–Presbyterian Hospital
264 Papers
632 Citations
Ori Ben-Yehuda is an academic researcher from NewYork–Presbyterian Hospital. The author has contributed to research in topics: Percutaneous coronary intervention & Medicine. The author has an hindex of 34, co-authored 213 publications. Previous affiliations of Ori Ben-Yehuda include Columbia University & Hospital Universitario La Paz.
Chat about Author
Papers
Outcomes Among Diabetic Patients Undergoing Percutaneous Coronary Intervention With Contemporary Drug-Eluting Stents: Analysis From the BIONICS Randomized Trial
Maayan Konigstein,Ori Ben-Yehuda,Pieter C. Smits,Michael P. Love,Shmuel Banai,Gidon Y. Perlman,Mordechai Golomb,Melek Ozgu Ozan,Mengdan Liu,Martin B. Leon,Gregg W. Stone,David E. Kandzari +11 more
TL;DR: Despite advances in interventional therapies, and the implementation of new-generation DES, diabetic patients still have worse angiographic and clinical outcomes compared with nondiabetic patients undergoing PCI.
51
Randomized Comparison of Ridaforolimus- and Zotarolimus-Eluting Coronary Stents in Patients With Coronary Artery Disease: Primary Results From the BIONICS Trial (BioNIR Ridaforolimus-Eluting Coronary Stent System in Coronary Stenosis).
David E. Kandzari,Pieter C. Smits,Michael P. Love,Ori Ben-Yehuda,Shmuel Banai,Simon D. Robinson,Michael Jonas,Ran Kornowski,Rodrigo Bagur,Andrés Iñiguez,Haim D. Danenberg,Robert L. Feldman,Rajiv Jauhar,Harish Chandna,Manish Parikh,Gidon Y. Perlman,Mercedes Balcells,Peter Markham,Melek Ozgu Ozan,Philippe Généreux,Elazer R. Edelman,Martin B. Leon,Gregg W. Stone +22 more
TL;DR: The safety and efficacy of a cobalt alloy-based coronary stent with a durable elastomeric polymer eluting the antiproliferative agent ridaforolimus for treatment of patients with coronary artery disease is undetermined as mentioned in this paper.
50
Long-term hepatic safety of ambrisentan in patients with pulmonary arterial hypertension.
Ori Ben-Yehuda,David J. Pizzuti,Andrea Brown,Marcus Littman,Hunter Gillies,Noreen Henig,Tobias Peschel +6 more
TL;DR: Liver toxicity is the most common reason for drug withdrawals and may not be detected in pre-marketing clinical trials, but in the case of drugs developed for orphan diagnoses, the clinical trial experience is invariably poor.
50
Prognostic Determinants of Coronary Atherosclerosis in Stable Ischemic Heart Disease: Anatomy, Physiology, or Morphology?
Amir Ahmadi,Gregg W. Stone,Jonathon Leipsic,Leslee J. Shaw,Todd C. Villines,Morton J. Kern,Harvey S. Hecht,David Erlinge,Ori Ben-Yehuda,Akiko Maehara,Eloisa Arbustini,Patrick W. Serruys,Hector M. Garcia-Garcia,Jagat Narula +13 more
TL;DR: The evidence for coronary anatomy, physiology, or plaque morphology is reviewed and potential algorithms that may enable a practical diagnostic and therapeutic strategy for the management of patients with stable ischemic heart disease are explored.
50
Long-Term Clinical Impact of Contrast-Associated Acute Kidney Injury Following PCI: An ADAPT-DES Substudy.
Reza Mohebi,Keyvan Karimi Galougahi,Javier García,Jennifer Horst,Ori Ben-Yehuda,Jai Radhakrishnan,Glenn M. Chertow,Allen Jeremias,David J. Cohen,Akiko Maehara,Gary S. Mintz,Shmuel Chen,Björn Redfors,Martin B. Leon,Thomas Stuckey,Michael J. Rinaldi,Giora Weisz,Bernhard Witzenbichler,Ajay J. Kirtane,Roxana Mehran,George Dangas,Gregg W. Stone,Ziad A. Ali +22 more
TL;DR: The ADAPT-DES (Assessment of Dual Antiplatelet Therapy with Drug Eluting Stents) study as mentioned in this paper was a prospective, multicenter registry of 8,582 patients treated with ≥ 1 drug-eluting stent(s).
49